Axoltis’ Phase II ALS trial fails; company points to exploratory endpoints

The ALS development space has been notoriously difficult for companies to navigate, with only three disease-modifying therapies currently FDA approved. The ALS development space has been notoriously difficult for companies to navigate, with only three disease-modifying therapies currently FDA approved. The biotech is working on exploratory data to progress the asset. Credit: Andrii Yalanskyi / Shutterstock.com Axoltis Pharma is undertaking additional analysis of its Phase II amyotrophic lateral sclerosis (ALS) trial after it failed to meet its primary endpoint. In patients treated with NX210c during the SEALS study (NCT06365216), there was no benefit in neurofilament light chain (NfL) levels or…

Source: Clinical Trials Arena